Table 4


All (N = 67)1040433078
CEBPA mutation (n = 12)5025503383
CEBPA wild type (n = 55)043402976
FLT3-ITD (n = 19)547321690
FLT3 wild type (n = 48)1038483475
BAALC high (n = 44)1630582172
BAALC high without FLT3/CEBPA mutation (n = 23)026702257
BAALC low (n = 23)061174896
BAALC low without FLT3/CEBPA mutation (n = 15)080753100
  • NOTE. Correlation of immunophenotypes and the CEBPA mutation status, the FLT3-ITD, and BAALC expression. Numbers indicate percentages patients in the respective group expressing a given marker. The cutoff for a positive result of a particular marker was set at >20%. Significant differences were seen for CD7 expression for patients with and without CEBPA mutations (P = 0.0023), and for CD11b (P = 0.019), CD34 (P = 0.001), CD15 (P = 0.044), and myeloperoxidase (P = 0.031) depending on high or low expression of BAALC. Differences for these markers were also significant between high and low BAALC expression when patients with FLT3-ITD or CEBPA mutations were excluded. No differences were detected in cells with FLT3 wild type versus ITD. No significant differences were detected in any groups for the lymphoid markers CD2, CD3, CD10, CD19, CD22, CD79, and the myeloid markers CD9, CD13, CD14, CD33, CD45, CD56, and for HLA-DR and TdT.